Biomarker Insights最新文献_第8页

Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4. 血清微纤维相关蛋白的昼夜、周与周和体育锻炼引起的变化

IF 3.8

Biomarker Insights Pub Date : 2021-05-14 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211016359

Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen

{"title":"Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4.","authors":"Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen","doi":"10.1177/11772719211016359","DOIUrl":"https://doi.org/10.1177/11772719211016359","url":null,"abstract":"Serum microfibrillar-associated protein 4 (sMFAP4) has been investigated as a biomarker for various diseases and is demonstrated to show significant gradual increase with severity of liver fibrosis. Ideal biomarkers used for disease diagnosis or prognosis should display deviating levels in affected individuals only and be robust to factors unrelated to the disease. Here we show the impact of normal physiological variation of sMFAP4 by characterizing the circadian variation, week-to-week variation, and physical exercise-induced levels. Serum samples from 3 groups of healthy volunteers were drawn: 7 times during a 24-hour period, 5 times during a 3-week period, and before and after a standardized physical exercise challenge. sMFAP4 was determined by AlphaLISA. Statistical analysis was performed using mixed effects modeling of repeated measurements. Circadian variation of sMFAP4 was demonstrated, with time of peak and nadir values depending on age and gender. For males, the peak values were observed during nighttime whereas for females, peak values were observed in the morning. Individual sMFAP4 levels remained stable over a period of 3 weeks and physical exercise inferred a mild negative influence. In conclusion, the circadian sMFAP4 variation was significant, and the levels could be influenced by physical activity. However, these variations were of limited magnitude relative to previously observed disease-induced levels in support of the biomarker potential of sMFAP4.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"16 ","pages":"11772719211016359"},"PeriodicalIF":3.8,"publicationDate":"2021-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211016359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38936847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches. 通过蛋白质组学和代谢组学方法发现多发性硬化症生物标志物。

IF 3.8

Biomarker Insights Pub Date : 2021-05-06 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013352

Ameneh Jafari, Amirhesam Babajani, Mostafa Rezaei-Tavirani

{"title":"Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches.","authors":"Ameneh Jafari, Amirhesam Babajani, Mostafa Rezaei-Tavirani","doi":"10.1177/11772719211013352","DOIUrl":"10.1177/11772719211013352","url":null,"abstract":"Multiple sclerosis (MS) is an autoimmune inflammatory disorder of the central nervous system (CNS) resulting in demyelination and axonal loss in the brain and spinal cord. The precise pathogenesis and etiology of this complex disease are still a mystery. Despite many studies that have been aimed to identify biomarkers, no protein marker has yet been approved for MS. There is urgently needed for biomarkers, which could clarify pathology, monitor disease progression, response to treatment, and prognosis in MS. Proteomics and metabolomics analysis are powerful tools to identify putative and novel candidate biomarkers. Different human compartments analysis using proteomics, metabolomics, and bioinformatics approaches has generated new information for further clarification of MS pathology, elucidating the mechanisms of the disease, finding new targets, and monitoring treatment response. Overall, omics approaches can develop different therapeutic and diagnostic aspects of complex disorders such as multiple sclerosis, from biomarker discovery to personalized medicine.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"16 ","pages":"11772719211013352"},"PeriodicalIF":3.8,"publicationDate":"2021-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e8/10.1177_11772719211013352.PMC8114757.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38933381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme. 精神高于物质:多形性胶质母细胞瘤死后脑生物银行面临的挑战。

IF 3.8

Biomarker Insights Pub Date : 2021-04-30 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013359

Cassandra Griffin, Ricardo Vilain, Simon King, Sandy Nixon, Alisha Gooley, Samara Bray, James Lynam, Marjorie M Walker, Rodney J Scott, Christine Paul

{"title":"Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme.","authors":"Cassandra Griffin, Ricardo Vilain, Simon King, Sandy Nixon, Alisha Gooley, Samara Bray, James Lynam, Marjorie M Walker, Rodney J Scott, Christine Paul","doi":"10.1177/11772719211013359","DOIUrl":"https://doi.org/10.1177/11772719211013359","url":null,"abstract":"Over the past 10 years, there has been limited progress for the treatment of brain cancer and outcomes for patients are not much improved. For brain cancer researchers, a major obstacle to biomarker driven research is limited access to brain cancer tissue for research purposes. The Mark Hughes Foundation Brain Biobank is one of the first post-mortem adult brain banks in Australia to operate with protocols specifically developed for brain cancer. Located within the Hunter New England Local Health District and operated by Hunter Cancer Biobank, the boundaries of service provided by the Brain Bank extend well into the surrounding regional and rural areas of the Local Health District and beyond. Brain cancer biobanking is challenging. There are conflicting international guidelines for best practice and unanswered questions relating to scientific, psychosocial and operational practices. To address this challenge, a best practice model was developed, informed by a consensus of existing data but with consideration of the difficulties associated with operating in regional or resource poor settings. The regional application of this model was challenged following the presentation of a donor located in a remote area, 380km away from the biobank. This required biobank staff to overcome numerous obstacles including long distance patient transport, lack of palliative care staff, death in the home and limited rural outreach services. Through the establishment of shared goals, contingency planning and the development of an informal infrastructure, the donation was facilitated within the required timeframe. This experience demonstrates the importance of collaboration and networking to overcome resource insufficiency and geographical challenges in rural cancer research programmes.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"16 ","pages":"11772719211013359"},"PeriodicalIF":3.8,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211013359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39930049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Quality Considerations When Using Tissue Samples for Biomarker Studies in Cancer Research. 在癌症研究中使用组织样本进行生物标记物研究时的质量考虑因素。

IF 3.8

Biomarker Insights Pub Date : 2021-04-20 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211009513

Valerie Speirs

引用次数: 0

Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. 生物标志物:当前监管环境下药物开发的机遇与挑战。

IF 3.8

Biomarker Insights Pub Date : 2020-12-08 eCollection Date: 2020-01-01 DOI: 10.1177/1177271920974652

Mariya Gromova, Annegret Vaggelas, Gabriele Dallmann, Diane Seimetz

{"title":"Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.","authors":"Mariya Gromova, Annegret Vaggelas, Gabriele Dallmann, Diane Seimetz","doi":"10.1177/1177271920974652","DOIUrl":"https://doi.org/10.1177/1177271920974652","url":null,"abstract":"Biomarkers are widely used at every stage of drug discovery and development. Utilisation of biomarkers has a potential to make drug discovery, development and approval processes more efficient. An overview of the current global regulatory landscape is presented in this article with particular emphasis on the validation and qualification of biomarkers, as well as legal framework for companion diagnostics. Furthermore, this article shows how the number of approved drugs with at least 1 biomarker used during development (biomarker acceptance) is affected by the recent advances in the biomarker regulations. More than half of analysed approvals were supported by biomarker data and there has been a slight increase in acceptance of biomarkers in recent years, even though the growth is not continuous. For certain pharmacotherapeutic groups, approvals with biomarkers are more common than without. Examples include immunosuppressants, immunostimulants, drugs used in diabetes, antithrombotic drugs, antineoplastic agents and antivirals. As a conclusion, potential benefits, challenges and opportunities of using biomarkers in drug discovery and development in the current regulatory landscape are summarised and discussed.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"15 ","pages":"1177271920974652"},"PeriodicalIF":3.8,"publicationDate":"2020-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1177271920974652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38732988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 33

A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression. 发现与慢性肾脏疾病进展相关的生物标志物的范例。

IF 3.8

Biomarker Insights Pub Date : 2020-12-01 eCollection Date: 2020-01-01 DOI: 10.1177/1177271920976146

Ibrahim Ali, Sara T Ibrahim, Rajkumar Chinnadurai, Darren Green, Maarten Taal, Tony D Whetton, Philip A Kalra

引用次数: 0

Biomarkers: Our Path Towards a Cure for Alzheimer Disease. 生物标志物:我们治疗阿尔茨海默病的途径。

IF 3.8

Biomarker Insights Pub Date : 2020-11-25 eCollection Date: 2020-01-01 DOI: 10.1177/1177271920976367

Rawan Tarawneh

{"title":"Biomarkers: Our Path Towards a Cure for Alzheimer Disease.","authors":"Rawan Tarawneh","doi":"10.1177/1177271920976367","DOIUrl":"https://doi.org/10.1177/1177271920976367","url":null,"abstract":"Over the last decade, biomarkers have significantly improved our understanding of the pathophysiology of Alzheimer disease (AD) and provided valuable tools to examine different disease mechanisms and their progression over time. While several markers of amyloid, tau, neuronal, synaptic, and axonal injury, inflammation, and immune dysregulation in AD have been identified, there is a relative paucity of biomarkers which reflect other disease mechanisms such as oxidative stress, mitochondrial injury, vascular or endothelial injury, and calcium-mediated excitotoxicity. Importantly, there is an urgent need to standardize methods for biomarker assessments across different centers, and to identify dynamic biomarkers which can monitor disease progression over time and/or response to potential disease-modifying treatments. The updated research framework for AD, proposed by the National Institute of Aging- Alzheimer's Association (NIA-AA) Work Group, emphasizes the importance of incorporating biomarkers in AD research and defines AD as a biological construct consisting of amyloid, tau, and neurodegeneration which spans pre-symptomatic and symptomatic stages. As results of clinical trials of AD therapeutics have been disappointing, it has become increasingly clear that the success of future AD trials will require the incorporation of biomarkers in participant selection, prognostication, monitoring disease progression, and assessing response to treatments. We here review the current state of fluid AD biomarkers, and discuss the advantages and limitations of the updated NIA-AA research framework. Importantly, the integration of biomarker data with clinical, cognitive, and imaging domains through a systems biology approach will be essential to adequately capture the molecular, genetic, and pathological heterogeneity of AD and its spatiotemporal evolution over time.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"15 ","pages":"1177271920976367"},"PeriodicalIF":3.8,"publicationDate":"2020-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1177271920976367","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38688446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Biobanking for Cancer Biomarker Research: Issues and Solutions. 癌症生物标志物研究的生物银行:问题与解决方案。

IF 3.8

Biomarker Insights Pub Date : 2020-10-19 eCollection Date: 2020-01-01 DOI: 10.1177/1177271920965522

Lise A Matzke, Peter H Watson

引用次数: 12

Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk. 簇蛋白作为肥胖相关阿尔茨海默病风险的潜在生物标志物

IF 3.8

Biomarker Insights Pub Date : 2020-10-12 eCollection Date: 2020-01-01 DOI: 10.1177/1177271920964108

David Bradley

{"title":"Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk.","authors":"David Bradley","doi":"10.1177/1177271920964108","DOIUrl":"https://doi.org/10.1177/1177271920964108","url":null,"abstract":"Over 35% of the adult US population is obese. In turn, excess adiposity increases the risk of multiple complications including type 2 diabetes (T2D), insulin resistance, and cardiovascular disease; yet, obesity also independently heightens risk of Alzheimer's Disease (AD), even after adjusting for other important confounding risk factors including blood pressure, sociodemographics, cholesterol levels, smoking status, and Apolipoprotein E (ApoE) genotype. Among patients over the age of 65 with dementia, 37% have coexisting diabetes, and an estimated 7.3% of cases of AD are directly attributable to midlife obesity. Clusterin, also known as apolipoprotein J (ApoJ), is a multifunctional glycoprotein that acts as a molecular chaperone, assisting folding of secreted proteins. Clusterin has been implicated in several physiological and pathological states, including AD, metabolic disease, and cardiovascular disease. Despite long-standing interest in elucidating clusterin's relationship with amyloid beta (Aβ) aggregation/clearance and toxicity, significant knowledge gaps still exist. Altered clusterin expression and protein levels have been linked with cognitive and memory function, disrupted central nervous system lipid flux, as well as pathogenic brain structure; and its role in cardiometabolic disease suggests that it may be a link between insulin resistance, dyslipidemia, and AD. Here, we briefly highlight clusterin's relevance to AD by presenting existing evidence linking clusterin to AD and cardiometabolic disease, and discussing its potential utility as a biomarker for AD in the presence of obesity-related metabolic disease.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"15 ","pages":"1177271920964108"},"PeriodicalIF":3.8,"publicationDate":"2020-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1177271920964108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38629754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Single Center "Snapshot" Experience With Donor-Derived Cell-Free DNA After Lung Transplantation. 单中心 "快照 "经验：肺移植术后的捐献者无细胞 DNA

IF 3.8

Biomarker Insights Pub Date : 2020-09-16 eCollection Date: 2020-01-01 DOI: 10.1177/1177271920958704

Deborah Jo Levine, David J Ross, Edward Sako

引用次数: 0